Plant-derived extracellular vesicles in musculoskeletal disorders: a narrative review of mechanisms, therapeutic efficacy, and translational prospects
Abstract
Musculoskeletal disorders (MSDs), including sarcopenia, osteoporosis, osteoarthritis, and rheumatoid arthritis, impose a growing global health burden, yet therapeutic options remain limited. Plant-derived extracellular vesicles (PDEVs), natural nanomedicines with multi-target potential, are emerging as promising candidates. This review examines preclinical evidence on PDEVs in MSDs, focusing on mechanisms, efficacy, and prospects. Preclinical studies indicate four interrelated mechanisms: gut microbiota remodeling, mitochondrial quality control, inflammation inhibition, and oxidative stress alleviation. PDEVs balance bone formation and resorption. In muscle, they preserve myofiber integrity via gut-muscle axis signaling, restore mitochondrial activity, and inhibit ubiquitin-proteasome-mediated degradation. In bone and joint, they promote osteoblast differentiation and chondrogenesis, suppress osteoclastogenesis, mitigate chondrocyte senescence, and inhibit synovial fibroblast activation. However, efficacy evidence remains limited because plant sources, isolation/characterization methods, models, doses, administration routes, and outcome assessments vary. Reporting of randomization, allocation concealment, blinding, sample-size calculation, and replication is often inadequate. Consequently, conclusions regarding PDEVs in MSDs remain hypothetical. Clinical translation requires standardized production, pharmacokinetic data, and long-term safety evaluation, as well as causal cross-species validation, multi-omics-based source screening, tissue-specific engineering, and rigorous trial validation.
Related
- Hydrogel-based delivery of extracellular vesicles for skin wound healing: design strategies, therapeutic mechanisms, and translational perspectives
- Targeting the NLRP3 inflammasome in rheumatoid arthritis fibroblast-like synoviocytes: pathogenic mechanisms, therapeutic strategies, and translational perspectives
- Interferential Current Therapy and Spray-And-Stretch in Musculoskeletal Disorders: A Narrative Review of Mechanisms, Evidence, and Clinical Positioning in the Absence of Direct Comparative Trials.
- Thioredoxin system: mechanisms and therapeutic potential in mental disorders
- Extracellular Vesicle Associated MicroRNAs in Vitiligo: A Systematic Review of Mechanisms and Translational Potential
BibTeX
@article{jiang2026plantderived,
title = {{Plant-derived extracellular vesicles in musculoskeletal disorders: a narrative review of mechanisms, therapeutic efficacy, and translational prospects}},
author = {Qixuan Jiang and Lei Chen and Junyan Li and Xiheng Lu and Wenlu Zhou and Ruofei Meng and Zhenyu Shi and Yiqing Ling and Ju Li and Taotao Xu},
journal = {Frontiers in Pharmacology},
year = {2026},
month = nov,
doi = {10.3389/fphar.2026.1989311},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1989311},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Plant-derived extracellular vesicles in musculoskeletal disorders: a narrative review of mechanisms, therapeutic efficacy, and translational prospects
AU - Qixuan Jiang
AU - Lei Chen
AU - Junyan Li
AU - Xiheng Lu
AU - Wenlu Zhou
AU - Ruofei Meng
AU - Zhenyu Shi
AU - Yiqing Ling
AU - Ju Li
AU - Taotao Xu
PY - 2026
DA - 2026/11/03
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1989311
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1989311
AB - Musculoskeletal disorders (MSDs), including sarcopenia, osteoporosis, osteoarthritis, and rheumatoid arthritis, impose a growing global health burden, yet therapeutic options remain limited. Plant-derived extracellular vesicles (PDEVs), natural nanomedicines with multi-target potential, are emerging as promising candidates. This review examines preclinical evidence on PDEVs in MSDs, focusing on mechanisms, efficacy, and prospects. Preclinical studies indicate four interrelated mechanisms: gut microbiota remodeling, mitochondrial quality control, inflammation inhibition, and oxidative stress alleviation. PDEVs balance bone formation and resorption. In muscle, they preserve myofiber integrity via gut-muscle axis signaling, restore mitochondrial activity, and inhibit ubiquitin-proteasome-mediated degradation. In bone and joint, they promote osteoblast differentiation and chondrogenesis, suppress osteoclastogenesis, mitigate chondrocyte senescence, and inhibit synovial fibroblast activation. However, efficacy evidence remains limited because plant sources, isolation/characterization methods, models, doses, administration routes, and outcome assessments vary. Reporting of randomization, allocation concealment, blinding, sample-size calculation, and replication is often inadequate. Consequently, conclusions regarding PDEVs in MSDs remain hypothetical. Clinical translation requires standardized production, pharmacokinetic data, and long-term safety evaluation, as well as causal cross-species validation, multi-omics-based source screening, tissue-specific engineering, and rigorous trial validation.
SN - 1663-9812
ER -